MetaCap

Kodiak Sciences (KOD) vs Twist Bioscience (TWST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kodiak Sciences (KOD) has outperformed Twist Bioscience (TWST) over the past year, gaining 367.8% versus a gain of 261.8%. Over five years, TWST leads with a +8.8% price change compared with +3.0% for KOD. Twist Bioscience is the larger company by market cap ($7.04 billion vs $6.35 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KOD+367.84%TWST+261.76%
+649%+309%-31%
Nov 21, 20251 yearNov 20, 2026
KOD-1.51%TWST-6.60%
+79%-14%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KOD versus TWST key metrics
MetricKODTWST
Share price$97.17$103.32
Market cap$6.35B$7.04B
1-day change-0.75%-7.44%
YTD return+247.53%+225.73%
1-year return+367.84%+261.76%
5-year return+3.04%+8.77%
EPS (TTM)$-4.08$-2.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$459.43M
Revenue growth (YoY)—+22.00%
Net income (latest FY)$-229.97M$-130.20M
Gross margin—52.41%
Operating margin—-30.35%
Net margin—-28.34%
52-week high$112.79$219.71
52-week low$20.38$28.27
Distance from 52-week high-13.85%-52.97%
Analyst consensusstrong_buybuy
Avg. price target upside+33.27%+24.68%
Average volume1.77M2.49M
Shares outstanding65.40M68.18M
Employees1441,080
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KOD has outperformed TWST by 106.1 percentage points over the past year.

About Kodiak Sciences

KOD stock →

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

About Twist Bioscience

TWST stock →

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,080 employees

KOD vs TWST FAQ

Which is bigger, Kodiak Sciences or Twist Bioscience?

Twist Bioscience (TWST) is larger, with a market capitalization of $7.04B compared with $6.35B for Kodiak Sciences (KOD).

Which stock has performed better over the past year, KOD or TWST?

KOD returned +367.84% over the past 12 months, compared with +261.76% for TWST (price return, excluding dividends). Past performance does not predict future results.

Are Kodiak Sciences and Twist Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons